Who owns Aktis Oncology, Inc. (AKTS)? Elite investor 13F holders
2 tracked elite investors reported holding Aktis Oncology, Inc as of 2026-09-30, including Renaissance Technologies LLC, Polen Capital Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors,…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | AKTIS ONCOLOGY INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 594594.00 USD | 30539.000000 | Shares | reduce | Original filing |
| Polen Capital Management | AKTIS ONCOLOGY INC | SHARE | 2026-09-30 | 2026-11-13 00:00:00 | 1417319.00 USD | 72795.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.